Consensus recommendations for the use of Ambulatory Glucose Profile in clinical practice


  • Stephan Matthaei Diabetes-Zentrum Quakenbrück, Fachabteilung für Diabetologie, Endokrinologie & Stoffwechselerkrankungen am Christlichen Krankenhaus, Quakenbrück, Germany
  • Ramiro Antuña DeAlaiz Diabeclinic, c/Corrida, 23 - 33206 Gijón, Spain
  • Emanuele Bosi Diabetes Research Institute, San Raffaele Hospital and San Raffaele Vita-Salute University, Via Olgettina, 60, 20132 Milan, Italy
  • Mark Evans Wellcome Trust/MRC Institute of Metabolic Science/Dept of Medicine, University of Cambridge, Level 4 IMS MRL, Box 289, Addenbrookes Hospital, Hills Road, Cambridge CB2 OQQ, UK
  • Nel Geelhoed-Duijvestijn Department of Internal Medicine, Medical Centre Haaglanden, Lijnbaan 32, 2512 VA, The Hague, The Netherlands
  • Michael Joubert Endocrinologie-Diabétologie, CHU de CAEN, Avenue de la Côte de Nacre, CS 30001, 14033 Caen, Cedex 9, France



Ambulatory Glucose Profile (AGP) is a way of displaying glucose data to reveal clinically relevant information. In a previously outlined study AGP was used to interpret glucose data recorded in patients with type 1 and 2 diabetes. These results, along with the published evidence and their own clinical experience, were discussed by an expert panel of diabetes specialists, with the aim of developing guidelines to assist clinicians in the analysis and interpretation of AGP.

This group supports the consensus view that the AGP can be an effective standard for the analysis of glucose data. Interpretation guidelines are reported in the form of an algorithm, developed to demonstrate a step-by-step approach in undertaking the analysis of an AGP report in clinical practice. These are expected to improve glycaemic control, and might help patients to better understand their glucose levels and become more involved in the management of their diabetes. Where hypoglycaemia is identified, the recommendation is to focus, as a priority, on its management. At the end of the consultation, one key message should be reinforced with the patient.


Mazze RS, Strock E, Wesley D, et al. Characterizing glucose exposure for individuals with normal glucose tolerance using continuous glucose monitoring and ambulatory glucose profile analysis. Diabetes Technol Ther 2008;10:140-59.

Bergenstal RM, Ahmann AJ, Bailey T, et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP). Diabetes Technol Ther 2013;15:198–211.

Serrano K. FDA supports standardized reporting and analysis on CGM devices. Diabetes Technol Ther 2013;15:348.

Kaufman FR. It’s time for a standard glucose report from CGM. Diabetes Technol Ther 2013;15:197.

Kowalski A, Dutta S. It’s time to move from the A1c to better metrics for diabetes control. Diabetes Technol Ther 2013;15:194-6.

Matthaei, S. Assessing the value of ambulatory glucose profile (AGP) in clinical practice. Br J Diabetes Vasc Dis 2014;4:148-52.

Dunn TC, Crouther N. Assessment of the variance of the ambulatory glucose profile over 3 to 20 days of continuous glucose monitoring. Diabetologia 2010;53 (Suppl. 1):S421.






Current Topics